Long-acting LY03009 to Begin Clinical Trials in China

Long-acting LY03009 to Begin Clinical Trials in China

310797

Long-acting LY03009 to Begin Clinical Trials in China

Clinical trials will begin soon in China to evaluate Luye Pharma’s LY03009, a once-a-month, extended-release investigational therapy to treat people with Parkinson’s disease.  A Phase 1 safety trial is underway in Australia, and the company said it also plans to begin clinical trials in the U.S.  Parkinson’s is characterized by the loss of brain nerve cells  that produce dopamine, a molecule (neurotransmitter) that sends messages between nerve cells. A lack of dopamine causes motor symptoms…

You must be logged in to read/download the full post.